Skip to content

Ketamine research published in 2024

Page 6 of 26: studies 101 to 120 of 518, newest first. Back to the ketamine overview

Studies

Improvement in pain by using lidocaine combined with esketamine in elderly patients receiving local anaesthesia for percutaneous kyphoplasty: a randomized controlled study.

BMC Anesthesiology October 23, 2024 Longyuan Zhou, Lei Lv, Ruilan Wu et al. 4 citations

Elderly patients often experience severe pain during percutaneous kyphoplasty under local anaesthesia. The aim of this work was to evaluate the effect of lidocaine combined with esketamine on pain improvement in elderly patients receiving local anaesthesia via percutaneous kyphoplasty. This prospective, randomized comparative trial was conducted on 66 elderly patients, aged 60-80 years, with an...

Local activity alterations in autism spectrum disorder correlate with neurotransmitter properties and ketamine induced brain changes.

medRxiv October 21, 2024 Pascal Grumbach, Jan Kasper, Joerg F. Hipp et al. 1 citation preprint

Autism spectrum disorder (ASD) is a neurodevelopmental condition associated with altered resting-state brain function. An increased excitation-inhibition (E/I) ratio is discussed as a potential pathomechanism but in-vivo evidence of disturbed neurotransmission underlying these functional alterations remains scarce. We compared rs-fMRI local activity (LCOR) between ASD (N=405, N=395) and...

DOI: 10.1101/2024.10.20.24315801 (opens in new tab) Full text (opens in new tab) Autism spectrum disorders Brain chemistry Neurotransmitters Ketamine research

Ketamine and Major Ketamine Metabolites Function as Allosteric Modulators of Opioid Receptors.

Molecular Pharmacology October 17, 2024 Ivone Gomes, Achla Gupta, Elyssa B Margolis et al. 21 citations

Ketamine is a glutamate receptor antagonist that was developed over 50 years ago as an anesthetic agent. At subanesthetic doses, ketamine and some metabolites are analgesics and fast-acting antidepressants, presumably through targets other than glutamate receptors. We tested ketamine and its metabolites for activity as allosteric modulators of opioid receptors expressed as recombinant receptors...

Exploring the Therapeutic Potential of N-Methyl-D-Aspartate Receptor Antagonists in Neuropathic Pain Management.

International Journal of Molecular Sciences October 16, 2024 Ciprian Pușcașu, Cornel Chiriță, Simona Negreș et al. 14 citations

Neuropathic pain (NeP) is a complex and debilitating condition that impacts millions of people globally. Although various treatment options exist, their effectiveness is often limited, and they can be accompanied by significant side effects. In recent years, there has been increasing interest in targeting the N-methyl-D-aspartate receptor (NMDAR) as a potential therapeutic approach to alleviate...

A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.

Journal of Affective Disorders October 15, 2024 Angela T H Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur et al. 13 citations

Ketamine and esketamine are increasingly prescribed in the treatment of resistant mood disorders and persons at risk of suicide. Ketamine is a drug of misuse with increasing non-therapeutic use in the general population. Herein, our aim was to determine whether ketamine and/or esketamine are disproportionately associated with reports of substance and/or alcohol misuse. Replicating a similar...

An evaluation of the efficacy and side effects of a single dose of ketamine in major depressive disorder.

Postgraduate Medical Journal October 14, 2024 Betül Uyar, Mehmet Güneş 1 citation

This study aims to provide a comprehensive overview of the antidepressant and antisuicidal efficacy of ketamine in patients with unipolar depression, with a focus on the clinical evidence and safety profile. In our study, the data of 120 major depressive disorder patients who received single-dose ketamine infusion therapy were evaluated retrospectively, with Montgomery-Asberg Depression Rating...

DOI: 10.1093/postmj/qgae142 (opens in new tab) Full text (opens in new tab) Single dose Suicide Depression treatment Ketamine therapy +3

Functional activity and connectivity signatures of ketamine and lamotrigine during negative emotional processing: a double-blind randomized controlled fMRI study.

Translational Psychiatry October 14, 2024 Marvin S Meiering, David Weigner, Matti Gärtner et al. 4 citations

Ketamine is a highly effective antidepressant (AD) that targets the glutamatergic system and exerts profound effects on brain circuits during negative emotional processing. Interestingly, the effects of ketamine on brain measures are sensitive to modulation by pretreatment with lamotrigine, which inhibits glutamate release. Examining the antagonistic effects of ketamine and lamotrigine on...

Long-Term Effects of Single and Repeated Ketamine Infusions on Treatment-Resistant Depression: A Retrospective Chart Review Study

Psychoactives October 12, 2024 Sofia Sakopoulos, Lisa D. Hinz 4 citations

Treatment-resistant depression (TRD) is a substantial public health burden with limited treatment options. Recent evidence suggests that single and repeated-dose ketamine infusions have rapid and significant antidepressant effects on individuals with TRD. Few studies have compared single or repeated (6) ketamine infusions past 14 days post-treatment. This retrospective chart review study...

Mental Health Facilities With Ketamine Infusion Therapy in the United States in 2020: Co-Location of Dual Diagnosis Mental Health and Substance Use Disorder Treatment

Carolina Digital Repository October 9, 2024 Orrin D. Ware

Ketamine is an anesthetic that has been identified as an effective therapy for depressive disorders and related symptoms. Some studies have identified ketamine as having the potential to reduce substance use among individuals with a substance use disorder (SUD)-alongside psychotherapy. Further, SUDs often co-occur with depressive disorders. Using the National Mental Health Services Survey 2020,...

DOI: 10.17615/rd8y-nq91 (opens in new tab) Ketamine Mental health Dual diagnosis Dual grammatical number +1

Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis.

European Archives of Psychiatry and Clinical Neuroscience October 9, 2024 Jiafeng Li, Ling Ma, Huan Sun et al. 5 citations

The current systematic review and meta-analysis examined the effect of racemic ketamine or esketamine on suicidal ideation in individuals with uni- or bipolar depression. We searched the MEDLINE, Embase, Central, PsycINFO, and Web of Science databases to identify randomized controlled trials that examined the effect of racemic ketamine or esketamine monotherapy on suicidal ideation (SI) in...

Association between pre-procedural anxiety and vomiting in children who undergo procedural sedation and analgesia in the emergency department.

BMC emergency medicine October 9, 2024 Elham Mahmoodi, Seyed Hossein Seyed Hosseini Davarani, Sarah Yang et al. 1 citation

Children presenting to the emergency department (ED) often require procedural sedation and analgesia (PSA) prior to procedures. Although ketamine is used widely for PSA safely, there is a risk of adverse effects. Among them, vomiting is significant as it occurs in about 10% of patients and can potentially endanger the airway. Because there is evidence that post-operative complications might be...

DOI: 10.1186/s12873-024-01097-5 (opens in new tab) Full text (opens in new tab) Children Vomiting Pediatric sedation Anxiety in medicine +3

Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms.

Biomedicines October 9, 2024 Piotr Kawczak, Igor Feszak, Tomasz Bączek 50 citations

Research over the past years has compared the enantiomers (S)-ketamine (esketamine) and (R)-ketamine (arketamine) of the previously known racemic mixture called ketamine (R/S-ketamine). Esketamine has been found to be more potent, offering three times stronger analgesic effects and 1.5 times greater anesthetic efficacy than arketamine. It provides smoother anesthesia with fewer side effects and...

The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists

American Journal of Psychiatry October 9, 2024 Caesar G. Imperio, Frances R. Levin, Diana Martínez 9 citations

Substance use disorder (SUD) is common in psychiatric patients and has a negative impact on health and well-being. However, SUD often goes untreated, and there is a need for psychiatrists, of all specialties, to address this pervasive clinical problem. In this review, the authors' goal is to provide a resource that describes treatments for SUD, using neuroscience as a framework. They discuss...

Results of esketamine administration in a Greek population; A case series.

Psychiatriki October 8, 2024 Petros Fotiadis, Eleni Tsalkitzi, Dimos Dimellis et al.

Esketamine is a non-selective, competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor in the brain. Through NMDA receptor antagonism, esketamine causes a transient increase in glutamate release, leading to increases in neurotrophic signaling and restoration of synaptic function in brain regions involved in mood regulation and emotional behavior. Several randomized clinical trials...

DOI: 10.22365/jpsych.2024.006 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Fast-acting antidepressant Mood disorders Therapeutic intervention +5

Presence of cholestasis and its impact on survival in SARS-CoV-2 associated acute respiratory distress syndrome.

Scientific Reports October 8, 2024 Mathias Schneeweiss-Gleixner, Katharina Krenn, Mathias Petter et al. 3 citations

Data on cholestasis and biliary injury in patients with COVID-19 are scarce. The primary aim of this study was to evaluate the prevalence of cholestasis and factors associated with its development and outcome in critically ill patients with COVID-19 associated acute respiratory distress syndrome (ARDS). In this retrospective exploratory study, COVID-19 patients with ARDS admitted to an...

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome.

npj Mental Health Research October 6, 2024 Jack D. C. Dahan, David Dadiomov, Tijmen Bostoen et al. 13 citations

There is some evidence that the subjective effects of ketamine and other psychedelics like psilocybin are crucial for their therapeutic outcomes, such as treatment of depression or substance use disorder (SUD). We performed a meta-analysis and systematic review on the correlation of subjective symptoms and dissociation versus ketamine-induced therapeutic outcomes in patients with depression or...

DOI: 10.1038/s44184-024-00091-w (opens in new tab) Full text (opens in new tab) Psychedelic therapy Therapeutic efficacy Mental health treatment Ketamine research +1

Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.

The Journal of Clinical Psychiatry October 2, 2024 Mia C Santucci, Mina Ansari, Sina Nikayin et al. 12 citations

Background: Bipolar disorder represents a significant source of morbidity and elevated mortality risk. Ketamine has emerged as a powerful antidepressant; however, there have been few trials of ketamine in bipolar depression and no trials with esketamine in bipolar depression, and few data exist from real-world settings. Here, we report outcomes from a cohort of patients with bipolar depression...

DOI: 10.4088/JCP.24m15376 (opens in new tab) Full text (opens in new tab) Ketamine therapy Bipolar disorder Depression treatment Clinical trials +1

Ketamine and Esketamine Use for Mood Disorders with Psychosis: A Systematic Review of Dissociative and Psychotic Symptoms

CNS Spectrums October 1, 2024 Renzo Costa, Ayyub Imtiaz, Jacob Adelman et al.

Introduction Ketamine is used off-label for suicidality and mood disorders, whereas esketamine is FDA-approved for treatment-resistant depression in adults. However, many of these studies have excluded patients with a history of or currently presenting with psychosis. A significant number of patients who have primary mood disorders with psychotic features need novel psychopharmacological...

Effect of Esketamine on Postoperative Delirium in Patients Undergoing Cardiac Valve Replacement with Cardiopulmonary Bypass: A Randomized Controlled Trial.

Anesthesia & Analgesia October 1, 2024 Xinglong Xiong, Yi Shao, Dongxu Chen et al. 41 citations

The aim of this study was to investigate the effects of esketamine on the risk of postoperative delirium (POD) in adults undergoing on-pump cardiac valve surgery. In this randomized, triple-blind, controlled trial, 116 adult patients with an American Society of Anesthesiologists (ASA) grade Ⅱ or Ⅲ and a New York Heart Association (NYHA) grade Ⅱ or Ⅲ who underwent cardiac valve surgery with...

Differential effects of repeated fluoxetine and ketamine administration on behavioral and pharmacological stressor-induced depression of digging behavior in mice.

Experimental and Clinical Psychopharmacology October 1, 2024 Kaitlyn J Partridge, Todd M. Hillhouse 1 citation

Major depressive disorder is a multifactorial disorder that originates from a complex web of variables and overlaps with similar disorders (e.g., depression and anxiety). As such, animal models should account for the considerable symptom overlap between psychiatric disorders. We sought to extend the findings of behavioral assays that encompass both anxiety and stress/depression components. To...

DOI: 10.1037/pha0000711 (opens in new tab) Full text (opens in new tab) Antidepressants Stress response Personalized medicine Psychiatric treatment +1